| Company/Division name | Bristol Myers Squibb |
| Parent company | Bristol Myers Squibb |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 500 |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 2300 |
| City reshored to: | Houston |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pharmaceutical drugs |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Customization/Flexibility, Eco-system synergies, Infrastructure, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D) |
